The rise of cancer immunotherapy instigated unique preclinical and translational challenges. In addition to immuno-oncology advances, we are ..
witnessing a new wave of targeted and novel therapies that enrich the arsenal of combination cancer therapies. The demand for predictive and robust preclinical models and approaches to minimize translational failures in oncology and immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions adds to the complexity of translational research in oncology and immuno-oncology. Cambridge Healthtech Institute’s 10th Annual Preclinical Strategies and Models in Oncology conference is designed as a forum for ideas and opinions exchange on how to decrease the rate of translational and clinical failures in oncology and immuno-oncology.